Shanghai JMT-Bio
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (30)
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Started: 3/6/2026
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Started: 7/23/2023
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Started: 12/16/2024
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Started: 4/3/2025
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Started: 2/18/2025
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Started: 10/23/2024
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Started: 2/6/2026
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Started: 10/1/2025
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Started: 4/26/2024
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid
Started: 4/5/2024
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
Started: 4/1/2023
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Started: 4/7/2022
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Started: 12/30/2025
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
Started: 6/30/2025
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Started: 6/15/2025
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Started: 4/1/2025
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Started: 4/1/2025
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Started: 11/21/2021
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
Started: 5/1/2024
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Started: 5/30/2026
Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants
Started: 1/26/2026
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Started: 4/11/2025
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Started: 12/17/2025
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia
Started: 9/9/2025
JMT106 Injection in the Treatment of Advanced Solid Tumors
Started: 9/25/2025
A Study of JMT203 in Patients With Cancer Cachexia
Started: 5/15/2024
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
Started: 10/12/2021
SYS6090 Combination Therapy in Advanced Lung Cancer
Started: 2/28/2026
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202
Started: 7/23/2024
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
Started: 10/31/2020